Clinical Trial Update: Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia [Phase 2]

View source ↗

Summary

Phase 2 trial update for PTG-300 in beta-thalassemia subjects with chronic anemia (both transfusion-dependent and non-transfusion-dependent) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Beta-thalassemia
• Ineffective Erythropoiesis

Drugs mentioned

• PTG-300

Snippet

Sponsor: Protagonist Therapeutics, Inc. | Conditions: β-thalassemia, Ineffective Erythropoiesis | Phase 2 | Status: COMPLETED